<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03049774</url>
  </required_header>
  <id_info>
    <org_study_id>EY201608</org_study_id>
    <nct_id>NCT03049774</nct_id>
  </id_info>
  <brief_title>A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor</brief_title>
  <official_title>A Retrospective Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angde Biotech Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angde Biotech Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this retrospective study is to review and describe the safety and the efficacy of
      recombinant human interleukin-11 (I) i (Baijieyi), using information already recorded in 20
      medical records, The time periods include May 8th of 2008 to december 31st of 2016.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 28, 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Days that platelet count firstly rebound to 75×10^9/L, 100×10^9/L, respectively, from the first time below 75×10^9/L at the chemotherapy cycle and the last chemotherapy cycle</measure>
    <time_frame>56 days</time_frame>
    <description>For prevention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days that platelet count firstly rebound to 75×10^9/L, 100×10^9/L</measure>
    <time_frame>28 days after the administration of Baijieyi</time_frame>
    <description>For treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the maximum and minimum platelet count at the chemotherapy cycle and the last chemotherapy cycle</measure>
    <time_frame>56 days</time_frame>
    <description>For prevention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the lasting days of platelet count below 50×10^9/L at the chemotherapy cycle and the last chemotherapy cycle</measure>
    <time_frame>56 days</time_frame>
    <description>For prevention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of platelet transfusions at the chemotherapy cycle and the last chemotherapy cycle</measure>
    <time_frame>56 days</time_frame>
    <description>For prevention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the percentage of patients whose platelet count firstly recovered above 75×10^9/L and 100×10^9/L</measure>
    <time_frame>28 days after the administration of Baijieyi</time_frame>
    <description>For treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the maximum and minimum platelet count, the lasting days of platelet count below 50×10^9/L</measure>
    <time_frame>28 days after the administration of Baijieyi</time_frame>
    <description>For treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of platelet transfusions</measure>
    <time_frame>28 days after the administration of Baijieyi</time_frame>
    <description>For treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events, serious adverse events, laboratory tests, ECG</measure>
    <time_frame>28 days after the administration of Baijieyi</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Chemotherapy-induced Thrombocytopenia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 20 clinical centers: subjects.who have received one or more injections of
        Baijieyi for treatment or prevention of chemotherapy-induced thrombocytopenia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. prescriptions explicitly given to the injection of Baijieyi;

          2. confirmed by histopathological or cytological examination of malignant tumors and
             chemotherapy;

          3. treatment: platelet count had reached below 75×10^9/L after the treatment of
             chemotherapy and before using Baijieyi; prevention: patients with chemotherapy at the
             beginning of the preventive administration of BaiJieyi, and chemotherapy is same with
             previous cycle;

          4. male or female, aged 18-85 years;

          5. The main research information required is complete.

        Exclusion Criteria:

          1. using other platelets of chemicals or biological products in the in the chemotherapy
             cycle used Baijieyi;

          2. using drugs which can cause thrombocytopenia in the in the chemotherapy cycle used
             Baijieyi;

          3. bone marrow dysfunction or bone marrow involvement;

          4. There are other causes of thrombocytopenia, such as aplastic anemia, acute leukemia,
             radiation sickness, immune thrombocytopenic purpura, and hypersplenism, in the course
             of the use of Baijieyi.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Liu</last_name>
      <phone>13910216310</phone>
      <email>13910216310@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuankai Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oprelvekin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

